XXXX in @entity2689 .

@entity1 @entity2194 @entity1569 @entity625 @entity1596 @entity262 @entity1103 @entity5502 @entity2689 @entity1829 @entity230 @entity2008 @entity792
BACKGROUND: @entity2689 is a @entity2008 where phenotypic females have either a missing X chromosome or a structural aberration of the X chromosome. Several @entity2194 have been associated with @entity2689 in the past, including one case only of proven @entity5502 . METHODS: In this study we report the clinical findings of three females with @entity2689 and @entity1596 followed up for a mean period of 12.6 months. Two were observed in childhood or adolescence (10 and 16 years old). RESULTS: All the @entity1 showed @entity5502 , in one case complicated by the onset of @entity1829 and @entity1103 . Associated @entity262 ( @entity1569 and @entity625 ) were diagnosed in two cases. The third @entity1 showed positive antinuclear antibody and HLA-DR11, without any clinical or radiologic signs of @entity625 . The @entity5502 tended to become chronic with time, and this may be partially due to the endocrinologic contraindications to the use of systemic @entity230 . Nevertheless, the final visual acuity was > or =8/10 in all three cases. CONCLUSIONS: @entity5502 should be included in the list of ocular manifestations in @entity2689 . It may tend to become chronic and may be found especially in those @entity1 presenting other associated @entity792 .
